Opendata, web and dolomites

EULAT Eradicate GBC SIGNED

Establishment and Exploitation of a European-Latin American Research Consortium towards Eradication of Preventable Gallbladder Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EULAT Eradicate GBC project word cloud

Explore the words cloud of the EULAT Eradicate GBC project. It provides you a very rough idea of what is the project "EULAT Eradicate GBC" about.

causal    detection    geographical    medicine    ethnic    plan    disease    lifestyle    incidence    precision    multifactorial    incidental    permit    industry    alterations    refine    huge    data    unravel    estimation    individualized    gender    identification    trials    secondary    tertiary    clinical    incorporation    environmental    surveillance    risk    therapy    molecular    genomic    health    epidemiological    considering    national    primary    generate    link    score    validate    training    regions    adequately    biorepository    participation    accuracy    biomarkers    integrates    platform    guiding    resource    personalized    removal    mechanisms    cancer    latin    omics    newly    gbc    policies    american    guarantees    generation    prevention    constitute    differences    patients    significantly    efficient    preventive    individuals    decisions    individual    pave    translational    gallbladder    functionally    prime    benefit    cultural    prediction    behavioural   

Project "EULAT Eradicate GBC" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITATSKLINIKUM HEIDELBERG 

Organization address
address: IM NEUENHEIMER FELD 672
city: HEIDELBERG
postcode: 69120
website: www.klinikum.uni-heidelberg.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 4˙675˙932 €
 EC max contribution 4˙675˙932 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2025-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITATSKLINIKUM HEIDELBERG DE (HEIDELBERG) coordinator 2˙362˙344.00
2    OSLO UNIVERSITETSSYKEHUS HF NO (OSLO) participant 762˙500.00
3    UNIVERSIDAD DE CHILE CL (SANTIAGO) participant 571˙000.00
4    UNIVERSITY OF BRISTOL UK (BRISTOL) participant 126˙337.00
5    INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS-INEN PE (LIMA) participant 125˙000.00
6    SANATORIO EL CARMEN SA AR (SALTA) participant 125˙000.00
7    Universidad Austral de Chile CL (VALDIVIA) participant 125˙000.00
8    UNIVERSIDAD CATÓLICA DEL MAULE CL (TALCA) participant 125˙000.00
9    UNIVERSIDAD DE LA FRONTERA CL (TEMUCO) participant 125˙000.00
10    UNIVERSIDAD MAYOR DE SAN SIMON BO (COCHABAMBA) participant 125˙000.00
11    PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE CL (SANTIAGO) participant 62˙500.00
12    KLINIKUM DER JOHANN WOLFGANG VON GOETHE UNIVERSITAET DE (FRANKFURT AM MAIN) participant 41˙250.00
13    CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER FR (LYON CEDEX 08) participant 0.00

Map

 Project objective

Gallbladder cancer (GBC) is a neglected disease with huge potential for prevention. This project aims at significantly improving the accuracy of risk estimation and early detection of GBC by identifying and adequately considering geographical, environmental, lifestyle, ethnic, gender and molecular differences. We plan to generate the information needed to establish and refine current prevention programmes, including the primary, secondary and tertiary prevention of GBC. We will (1) build a unique European–Latin American GBC biorepository integrated into a tailored IT platform, (2) identify, validate and functionally characterize novel GBC biomarkers, (3) develop a multifactorial risk score that integrates established and newly identified epidemiological and molecular risk factors, (4) improve the understanding of the causal mechanisms that link lifestyle, cultural and behavioural factors to GBC development, (5) unravel novel opportunities for the targeted therapy of incidental GBC, (6) exploit existing and newly generated epidemiological and multi-omics data to improve the accuracy of GBC risk prediction and (7) contribute to the training of the next generation of Latin American researchers in precision medicine for GBC. The generated information will permit identification of individuals at high GBC risk, guiding surveillance and individual decisions on the possible benefit of preventive gallbladder removal in regions of low and high GBC incidence. Novel data on genomic alterations in incidental GBC will pave the way towards implementation of future clinical trials. The planned European–Latin American GBC biorepository and IT platform will constitute a prime resource for translational research on individualized prevention, personalized early detection and targeted therapy of GBC. The participation in our project of representatives of health authorities, patients and the industry guarantees the efficient incorporation of project results into national health policies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EULAT ERADICATE GBC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EULAT ERADICATE GBC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More